A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease

Alpha [NCT01524887]

Description: The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.

Biological: Immune Globulin Intravenous (Human), 10% Solution; Biological: Human albumin 0.25%

Primary Investigator: Kereiakes

Drug/Device Information
Mild to moderate Alzheimer’s disease
Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) versus Human albumin 0.25%
Dosage frequency: Intravenously every 2 weeks
Baxter Healthcare Corporation